Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Inspire Medical Systems in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Inspire Medical Systems’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001609550-26-000023
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of goods sold | 27,671 | 30,709 |
| Gross profit | 176,912 | 170,608 |
| Operating expenses: | ||
| Research and development | 25,826 | 27,803 |
| Selling, general and administrative | 152,204 | 144,290 |
| Total operating expenses | 178,030 | 172,093 |
| Operating (loss) | (1,118) | (1,485) |
| Interest and dividend (income), net | (3,741) | (5,066) |
Item 1. Financial Statements.
FAQ
- What is Inspire Medical Systems's R&D?
- Inspire Medical Systems (INSP) reported R&D of $25.83M in Q1 2026.
- How has Inspire Medical Systems's R&D changed year-over-year?
- Inspire Medical Systems's R&D decreased by 7.1% year-over-year, from $27.8M to $25.83M.
- What is the long-term trend for Inspire Medical Systems's R&D?
- Over 4 years (2021 to 2025), Inspire Medical Systems's R&D has grown at a 28.9% compound annual growth rate (CAGR), from $37.35M to $103.17M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Inspire Medical Systems's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude